Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/16
C07K-014/00
출원번호
US-0155514
(2002-05-23)
등록번호
US-7304033
(2007-12-04)
발명자
/ 주소
Larsen,Christian P.
Pearson,Thomas C.
Adams,Andrew B.
Peach,Robert J.
Linsley,Peter S.
Naemura,Joseph Roy
Bajorath,Jurgen
출원인 / 주소
Bristol Myers Squibb Company
대리인 / 주소
Mandel & Adriano
인용정보
피인용 횟수 :
35인용 특허 :
30
초록
The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.
대표청구항▼
What is claimed is: 1. A method for inhibiting islet cell transplant rejection in a subject, comprising administering to the subject an effective amount of a CTLA4 molecule comprising a mutated extracellular domain comprising an amino acid sequence beginning with alanine at position 26 and ending w
What is claimed is: 1. A method for inhibiting islet cell transplant rejection in a subject, comprising administering to the subject an effective amount of a CTLA4 molecule comprising a mutated extracellular domain comprising an amino acid sequence beginning with alanine at position 26 and ending with aspartic acid at position 150 as shown in SEQ ID NO:6, or beginning with methionine at position 27 and ending with aspartic acid at position 150 as shown in SEQ ID NO:6. 2. A method for treating diabetes by inhibiting islet cell transplant rejection in a subject by the method of claim 1. 3. The method of claim 1, wherein the islet cells are encapsulated prior to administration to the subject. 4. The method of claim 1, further comprising administering to the subject an effective amount of at least one of an immunosuppressive agent, an immunomodulatory compound, and an anti-inflammatory agent, wherein the CTLA4 molecule and at least one of an immunosuppressive agent, an immunomodulatory compound and an anti-inflammatory agent are to be administered concomitantly or in sequence. 5. The method of claim 4, wherein the immunosuppressive agent is (i) rapamycin (sirolimus) or its derivative 40-O-(2-hydroxy)ethyl-rapamycin, (ii) anti-human IL-2R mAb, or (iii) a combination of (i) and (ii). 6. The method of claim 4, wherein the immunosuppressive agent is a cyclosporin, tacrolimus, prednisone, azathioprine, methotrexate, infliximab, hydroxychloroquine, sulphasalazopryine, etanercept, anakinra, basiliximab, chloroquine, cyclophosphamide, cytoxan, 15-deoxyspergualine, D-penicillamine, glatiramer acetate, FTY720, horse anti-human thymocyte globulin (ATGAM), humanized anti-TAC (HAT), interferon beta-1a, interferon beta-1b, leflunomide, lymphocyte immune globulin, methoxsalen, mitoxantrone hydrochloride, mycophenolic acid, mycophenolate mofetil, mizoribine, rabbit anti-human thymocyte globulin, Rho (D) immune globulin, sirolimus (rapamycin), sulfasalzine, thalidomide, soluble gp39, soluble CD29, soluble CD40, soluble CD80, soluble CD86, soluble CD28, soluble CD56, soluble Thy-1, soluble CD3, soluble TCR, soluble VLA-4, soluble VCAM-1, soluble LECAM-1, soluble ELAM-1, soluble CD44, antibodies to gp39, antibodies to CD40, antibodies to B7-1 or B7-2, antibodies to CD28, antibodies to LFA-1, antibodies to LFA-2, antibodies to IL-2, antibodies to IL 12, antibodies to IFN-gamma, antibodies to CD2, antibodies to CD48, antibodies to any ICAM, antibodies to CTLA4, antibodies to Thy-1, antibodies to CD56, antibodies to CD3, antibodies to CD29, antibodies to TCR, antibodies to VLA-4, antibodies to VCAM-1, antibodies to LECAM-1, antibodies to ELAM-1, antibodies to CD44, monoclonal antibodies to OX40, or 4-1BB CTLA4/CD28-1g, anti-human IL-2R mAbs, 40-0(2hydroxy)ethyl-rapamycin, soluble CD80 deposited as ATCC 68627, an antibody to any of ICAM-1, ICAM-2 and ICAM-3, or a monoclonal antibody to any of MHC, CD2, CD3, CD4, CD11a/CD18, CD7, CD25, CD27, B7, CD40, CD45, CD58, CD137, ICOS, or CD150 (SLAM). 7. The method of claim 4, wherein administration is by intravenous injection, intramuscular injection, subcutaneous injection, implantable pump, continuous infusion, gene therapy, liposomes or oral administration. 8. The method of claim 1, wherein the subject is a human, non-human primate, rabbit, sheep, rat, dog, cat, pig, or mouse. 9. The method of claim 1 further comprising administering T cell depleted bone marrow cells to the subject. 10. The method of claim 1, wherein the subject is being transplanted with islet cells before, or after, administration of the CTLA4 molecule. 11. The method of claim 2, wherein diabetes is type 1 diabetes or type 2 diabetes. 12. The method of claim 1, wherein the mutated extracellular domain is fused to a non-CTLA4 moiety. 13. The method of claim 12, wherein the non-CTLA4 moiety comprises an immunoglobulin moiety. 14. The method of claim 13, wherein the immunoglobulin moiety is an immunoglobulin constant region or portion thereof. 15. The method of claim 14, wherein the immunoglobulin constant region or portion thereof comprises one or more mutations to reduce effector function. 16. The method of claims 14 or 15, wherein the immunoglobulin constant region comprises the hinge, CH2 and CH3 regions of an immunoglobulin molecule. 17. The method of claim 14, wherein the immunoglobulin constant region or portion thereof is a human or monkey immunoglobulin constant region. 18. A method for inhibiting islet cell transplant rejection in a subject, comprising administering to the subject an effective amount of a soluble CTLA4 mutant molecule, wherein the soluble CTLA4 mutant molecule comprises an amino acid sequence as shown in SEQ ID NO:6 beginning with alanine at position 26 and ending with lysine at position 383, or beginning with methionine at position 27 and ending with lysine at position 383. 19. The method of claims 1 or 18 further comprising administering to the subject an effective amount of an immunosuppressive agent. 20. The method of claim 19, wherein the immunosuppressive agent is glucocorticoid-free. 21. The method of claim 19, wherein the immunosuppressive agent is calcineurin inhibitor-free. 22. The method of claim 19, wherein the immunosuppressive agent comprises (i) rapamycin (sirolimus) or its derivative 40-O-(2-hydroxy)ethyl-rapamycin, (ii) anti-IL-2R monoclonal antibody, or (iii) a combination of (i) and (ii). 23. The method of claim 22, wherein the anti-IL-2R monoclonal antibody is basiliximab. 24. A method for inhibiting islet cell transplant rejection in a subject, comprising administering to the subject an effective amount of a soluble CTLA4 mutant molecule encoded by DNA deposited as ATCC number PTA-2104. 25. A method for inhibifmg islet cell transplant rejection in a subject, comprising administering to the subject an effective amount of a soluble CTLA4 mutant molecule expressed by DNA deposited as ATCC number PTA-2104. 26. The method of claims 24 or 25, further comprising administering to the subject an effective amount of an immunosuppressive agent. 27. The method of claim 26, wherein the immunosuppressive agent is glucocorticoid-free. 28. The method of claim 26, wherein the immunosuppressive agent is calcineurin inhibitor-free. 29. The method of claim 26, wherein the immunosuppressive agent comprises (i) rapamycin (sirolimus) or its derivative 40-O-(2-hydroxy)ethyl-rapamycin, (ii) an anti-IL-2R monoclonal antibody, or (iii) a combination of (i) and (ii). 30. The method of claim 29, wherein the anti-IL-2R monoclonal antibody is basiliximab. 31. The method of claims 1 or 4, wherein the CTLA4 molecule is encoded by DNA deposited as ATCC number PTA 2104. 32. The method of claims 1 or 4, wherein the CTLA4 molecule is expressed by DNA deposited as ATCC number PTA 2104.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (30)
Linsley Peter S. (Seattle WA) Ledbetter Jeffrey A. (Seattle WA) Damle Nitin K. (Renton WA) Brady William (Bothell WA), B7IG fusion protein.
Linsley Peter S. (Seattle WA) Ledbetter Jeffrey A. (Seattle WA) Damle Nitin K. (Renton WA) Brady William (Bothell WA), Chimeric CTLA4 receptor and methods for its use.
Ledbetter Jeffrey A. (Seattle WA) Gilliland Lisa K. (Seattle WA) Hayden Martha S. (San Diego CA) Linsley Peter S. (Seattle WA) Bajorath Jurgen (Everett WA) Fell H. Perry (Redmond WA), Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion pr.
Ledbetter Jeffrey A. ; Gilliland Lisa K. ; Hayden Martha S. ; Linsley Peter S. ; Bajorath Jurgen ; Fell H. Perry, Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell.
Anderson Darrell R. ; Brams Peter ; Hanna Nabil ; Shestowsky William S. ; Heard Cheryl, Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies.
Carl H. June ; Craig B. Thompson ; Gary J. Nabel ; Gary S. Gray ; Paul D. Rennert, Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells.
Larsen Christian P. ; Aruffo Alejandro A. ; Hollenbaugh Diane L. ; Linsley Peter S. ; Ledbetter Jeffrey A. ; Pearson Thomas C., Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use.
Linsley Peter S. ; Kay Mark A. ; Wilson Christopher B. ; Ledbetter Jeffrey ; Aruffo Alejandro A. ; Hollenbaugh Diane L., Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 l.
Linsley Peter S. ; Ledbetter Jeffrey A. ; Damle Nitin K. ; Brady William ; Wallace Philip M., Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules.
Gribben, John G.; Freeman, Gordon J.; Nadler, Lee M.; Rennert, Paul; Jellis, Cindy L.; Greenfield, Edward; Gray, Gary S., Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Dinarello, Charles A.; Lewis, Eli C., Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity.
Dinarello, Charles A.; Lewis, Eli C., Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Vratsanos, George; Becker, Jean-Claude; Corbo, Michael, Method for retarding progression to definite rheumatoid arthritis in subjects with undifferentiated arthritis.
Cohen, Robert; Carr, Suzette; Hagerty, David; Peach, Robert James; Becker, Jean-Claude, Method for treating a rheumatic disease using a soluble TLA4 molecule.
Cohen, Robert; Carr, Suzette; Hagerty, David; Peach, Robert James; Becker, Jean-Claude, Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID.
Vratsanos, George; Becker, Jean-Claude; Corbo, Michael, Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis.
Larsen, Christian P.; Pearson, Thomas C.; Adams, Andrew B.; Peach, Robert J.; Linsley, Peter S.; Naemura, Joseph Roy; Bajorath, Jurgen, Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules.
Cohen, Robert; Belder-Carr, Suzette; Hagerty, David; Peach, Robert James; Becker, Jean-Claude, Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule.
Cohen, Robert; Carr, Suzette; Hagerty, David; Peach, Robert James; Becker, Jean-Claude, Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.